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Abstract
We present a case of a 79-year-old woman admitted to our hospital with pain in the right upper
abdominal quadrate radiated to the back, jaundice, fever and chills. The laboratory tests showed
serum carbohydrate antigen 19-9 levels of 99.070 U/ml (normal values: 0-37 U/ml). The rest of the
biochemistry showed alkaline phosphatase of 550 IU/l, direct bilirubin: 17.5 mg/dl, total bilirubin:
28.4 mg/dl. Abdominal sonography demonstrated dilated common bile duct. Two weeks
postoperatively, the carbohydrate antigen 19-9 fell to 970 U/ml and returned within normal range
(31 U/ml) two months later. Furthermore, the magnetic resonance cholangiopancreatography
performed postoperatively demonstrated normal configuration of the biliary tree and the common
bile duct.
Introduction
Carbohydrate Antigen (CA) 19-9, discovered by
Koprowski et al [1] is a gastrointestinal cancer-related
antigen measured by a monoclonal antibody, which
shows a high positivity in pancreato-biliary malignancies.
However, high levels of serum CA 19-9 is occasionally
found in benign disease of the liver, pancreas and biliary
tract, especially in cases with gall stone disease in which
the high rate of its elevation has been reported in acute
stage, but the value is usually below 5.000 U/ml [2,3].
We report a case of common bile duct stone with acute
cholangitis presenting with extraordinarily high serum
CA 19-9 levels, which returned to the normal after
surgical removal of the stone.
Case presentation
A 79-year-old woman Caucasian woman was admitted
with the chief complaints of epigastralgia with radiation to
the back and jaundice for about ten days. Fever and chills
were noted for seven days. The laboratory data were as
follow: white blood cell count of 12.020/μl (normal
values: 3900-10600/μl), alanine aminotransferase:
350IU/l(normalrange:10-35IU/l),alkalinephosphatase:
550 IU/l (normal range: 30-125 IU/l), direct bilirubin:
17.5 mg/dl (normal values: 0.01-0.2 mg/dl), total
bilirubin: 28.4 mg/dl (normal values: 0.1-1 mg/dl), CA
19-9: 99.070 U/l (normal value: 0-37 U/l). Abdominal
sonography showed dilatation of the common bile duct
(maximum diameter: 1.3 cm) (Figure 1).
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chotomy were performed. Upon opening the dilated
common bile duct choledochoscopy was done and a
stone was noted and removed at the distal common bile
duct measured about 1.2 cm in diameter. The common
bile duct was closed with T-tube. Two weeks after the
operation, the CA 19-9 fell to 970 U/ml and returned
to the normal range (31 U/ml) two months later.
Postoperatively, the magnetic resonance cholangiopan-
creatography (MRCP) showed normal configuration of the
biliary tree and the common bile duct (Figure 2A, B).
Discussion
CA 19-9, carbohydrate antigen that was defined by
monoclonal antibody to the cultured cell from human
colonic cancer, was termed by Korprowski in 1979 [1].
Initially was considered to be a tumor marker associated
with colon cancer, but later became a useful tumor marker
for pancreatobiliary malignancies.
CA 19-9 is produced in normal human pancreatic and
biliary ductal cells. Since the exact pathway between tissue
andbloodisstillnotwellknown,therealmechanismofthe
elevated serum CA 19-9 remains unsettled [4]. A CA 19-9
value of more than 1.000 U/ml usually indicates a
gastrointestinal cancer and has been reported to have
specificity greater than 99% for pancreatic cancer, never-
theless,false-positiveresultscanbefoundtobenigndisease
suchaspancreatitisorlivercirrhosis[5].Also,iswellknown
that elevated CA 19-9 in the sera may occur in various
benign diseases such as gall bladder stone disease, chronic
pancreatitis, hepatitis, liver cirrhosis, renal failure, duode-
nal ulcer, gastric polyps, colonic polyps and renal cyst.
The percentage of patients with a serum CA 19-9 level
more than 10.000 U/ml is reported to be 6-31% in
pancreatic cancer and 0-30% in biliary tract cancer [6].
There are few reports however, of gall stone patients
with such a high serum levels of CA 19-9. There have
been only two cases of common bile duct stone with
a serum CA 19-9 level greater than 10.000 U/ml in the
literature [2,7].
Surprisingly, extremely elevated serum CA 19-9 in patients
with acute cholangitis like the reported case may occur.
Murohisa et al [8] presented a case of bile duct stone with
cholangitis and high serum CA 19-9 level (60.000 U/ml),
which returned to the normal 6 weeks later. In our
reported case, the serum CA 19-9 value returned to the
normal two months later.
Production and secretion of CA 19-9 from malignant cells
are considered to be responsible for the high serum
CA 19-9 level in malignancies. The real reason for the CA
19-9 elevation in acute cholangitis is not clear. Several
mechanisms have been postulated as: 1) leakage of
condensed CA 19-9 due to biliary tract obstruction from
the bile into blood circulation [9], 2) CA 19-9 production
by irritated bile duct cells exposed to increased biliary
pressure may be enhanced, 3) enhanced production of
CA 19-9 in the bile duct epithelium and the mucosa of
gall bladder induced by the inflammatory process, 4)
the inflammatory cytokines produced in sepsis due
to cholangitis probably have some contribution.
Though the presence of a gastrointestinal cancer may
enhance the production of CA 19-9, extreme elevation of
CA 19-9 could occur in benign biliary obstruction and
inflammation as in our reported case. The precise
mechanism for this abnormal high levels remains to be
clarified.
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Figure 1. Abdominal sonography showed dilatation of the
common bile duct.
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Figure 2A and B. The MRCP performed two months postoperatively demonstrated normal configuration of the intrahepatic
biliary tract and the common bile duct.
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